(Total Views: 645)
Posted On: 10/25/2021 5:16:12 PM
Post# of 22467
Possibly James Miller?
https://www.linkedin.com/in/james-miller-305165b/
Started Aug 2021 on the QMC Board of Advisors
Executive Vice President at F3 Platform Biologics
https://www.f3pb.com/
James R. Miller has held senior executive positions in large pharmaceutical/biotechnology companies including: Vice President & General Manager, Talecris Biotherapeutics; Vice President, International, Medimmune/Astra Zeneca; and Vice President, International Marketing and Business Development, Abbott Laboratories (now AbbVie). Mr. Miller also held several other management and finance positions at Abbott over his 13 year tenure at that company. Responsibilities in these positions ranged from establishing an international presence for Medimmune and Talecris to managing an $800 million European pharma business for Abbott Laboratories.
Mr. Miller co-founded Pinnacle Biologics to create new opportunities with FDA-approved indication of F3’s lead drug candidate, AmiGuard CT. Mr. Miller has continually believed in the potential for additional applications of amifostine, as evidenced by his revival of the Medimmune international sales of Ethyol (amifostine) in 15 markets in Europe, which included establishing a contract sales force, distribution, pharmacovigilance, and finance network, as well as his establishment of Pinnacle Biologics for continued support of Ethyol in Europe. Mr. Miller’s efforts allowed the company to secure more assets to further develop amifostine, as well as to secure valuable amifostine intellectual property coupled with key relationships with the top radiation oncologists in the world. Mr. Miller has a degree in Accounting and was a former CPA for Deloitte.
https://www.linkedin.com/in/james-miller-305165b/
Started Aug 2021 on the QMC Board of Advisors
Executive Vice President at F3 Platform Biologics
https://www.f3pb.com/
James R. Miller has held senior executive positions in large pharmaceutical/biotechnology companies including: Vice President & General Manager, Talecris Biotherapeutics; Vice President, International, Medimmune/Astra Zeneca; and Vice President, International Marketing and Business Development, Abbott Laboratories (now AbbVie). Mr. Miller also held several other management and finance positions at Abbott over his 13 year tenure at that company. Responsibilities in these positions ranged from establishing an international presence for Medimmune and Talecris to managing an $800 million European pharma business for Abbott Laboratories.
Mr. Miller co-founded Pinnacle Biologics to create new opportunities with FDA-approved indication of F3’s lead drug candidate, AmiGuard CT. Mr. Miller has continually believed in the potential for additional applications of amifostine, as evidenced by his revival of the Medimmune international sales of Ethyol (amifostine) in 15 markets in Europe, which included establishing a contract sales force, distribution, pharmacovigilance, and finance network, as well as his establishment of Pinnacle Biologics for continued support of Ethyol in Europe. Mr. Miller’s efforts allowed the company to secure more assets to further develop amifostine, as well as to secure valuable amifostine intellectual property coupled with key relationships with the top radiation oncologists in the world. Mr. Miller has a degree in Accounting and was a former CPA for Deloitte.
(0)
(0)
